Show simple item record

dc.contributor.authorTrabert, Britton
dc.contributor.authorWaterboer, Tim
dc.contributor.authorIdahl, Annika
dc.contributor.authorBrenner, Nicole
dc.contributor.authorBrinton, Louise A
dc.contributor.authorButt, Julia
dc.contributor.authorCoburn, Sally B
dc.contributor.authorHartge, Patricia
dc.contributor.authorHufnagel, Katrin
dc.contributor.authorInturrisi, Federica
dc.contributor.authorLissowska, Jolanta
dc.contributor.authorMentzer, Alexander
dc.contributor.authorPeplonska, Beata
dc.contributor.authorSherman, Mark E
dc.contributor.authorWills, Gillian S
dc.contributor.authorWoodhall, Sarah C
dc.contributor.authorPawlita, Michael
dc.contributor.authorWentzensen, Nicolas
dc.date.accessioned2019-03-28T10:56:19Z
dc.date.available2019-03-28T10:56:19Z
dc.date.issued2019-02-01
dc.identifier.citationJ Natl Cancer Inst. 2019 111(2):129-136.en_US
dc.identifier.issn1460-2105
dc.identifier.pmid29790947
dc.identifier.doi10.1093/jnci/djy084
dc.identifier.urihttp://hdl.handle.net/10146/618290
dc.description.abstractPelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations. Studies included: 1) a case-control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case-control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression. In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR = 2.00, 95% CI = 1.38 to 2.89; cut-point 3 [max OR]: OR = 2.19, 95% CI = 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR = 1.43, 95% CI = 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR = 2.25, 95% CI = 1.07 to 4.71); cut-point 3: OR = 2.53, 95% CI = 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk. In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer.en_US
dc.language.isoenen_US
dc.relation.urlhttps://academic.oup.com/jnci/article/111/2/129/5001107en_US
dc.subjectantibodiesen_US
dc.titleAntibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations.en_US
dc.typeArticleen_US
dc.contributor.departmentnen_US
dc.identifier.journalJNCI: Journal of the National Cancer Instituteen_US
dc.source.journaltitleJournal of the National Cancer Institute
refterms.dateFOA2019-03-28T10:56:20Z


Files in this item

Thumbnail
Name:
antibodies.pdf
Size:
725.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record